Lupin has launched Formoflo-G MDI, the world's first fixed-dose triple combination Metered-Dose Inhaler (MDI) for Chronic Obstructive Pulmonary Disease (COPD) in India, following approval from the Drugs Controller General of India (DCGI). The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD.

Lupin Formoflo-G is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability.

Commenting on the launch, Nilesh Gupta, Managing Director, Lupin, said, "As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases."

Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies.

Rajeev Sibal, President–India Region Formulations, Lupin, said ,“Formoflo-G MDI marks an important addition to our respiratory portfolio, bringing together 3 established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes."